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Infections in dialysis and transplant patients in tropical coun- In contrast, the lack of transplant registries has prevented
tries. Infections complicate the course of 50–75% of transplant a systematic study of the etiology and course of post-
recipients in the tropical countries, with a mortality of 20–60%. transplant infections in tropical countries. Most of theFactors contributing to this dismal outcome include unhygienic
available data are based on the experience of individualconditions, hot and humid climate, late presentation, lack of
physicians from a limited number of centers. It is esti-knowledge about the spectrum of organisms in these areas,
scanty diagnostic techniques, and high cost of lifesaving antimi- mated that infections complicate the course of 50–75% of
crobial agents. Most of the infections are endemic in these transplant recipients in tropical countries, with mortality
regions. Besides the universally encountered bacterial infec- ranging from 20–60% [8–16]. The factors contributingtions, 7–10% of patients on maintenance dialysis and 10–13%
to this dismal outcome include unhygienic conditions,of transplant recipients develop tuberculosis. The prevalence
hot and humid climate, late presentation, a lack of knowl-of hepatitis B virus (HBV) varies from 20–45% and that of
hepatitis C virus (HCV) from 7–60% in dialysis patients. These edge about the spectrum of organisms in these areas, and
figures are significantly higher than their prevalence in the high cost of life-saving antimicrobial agents. Sensitive
general populations in these regions. The incidence of cytomeg- diagnostic techniques such as tissue biopsy, antigen de-alovirus (CMV) disease at autopsy has shown an increase from
tection, polymerase chain reaction, and culture facilities4% in the pre-cyclosporine era to 17% after introduction of
for isolating viruses and unusual bacteria and fungi usedcyclosporine to the immunosuppressive regimes at our center.
Coinfection with other bacterial or fungal organisms is ob- routinely in the West are either not available or are too
served more frequently in CMV infected allograft recipients. expensive. Autopsies are not done, and the cause of
Clinical and autopsy studies have revealed the incidence of death remains unknown in the vast majority of theseopportunistic fungal infections in allograft recipients between
patients. Since most patients cannot afford long-term4–7%, which is likely to be an underestimate. These fungal
maintenance dialysis or a second transplant in the eventinfections carried a high mortality of over 65% at our center.
The protean manifestations with which the opportunistic infec- of graft loss due to rejection, immunosuppressive therapy
tions present in immunosuppressed patients and lack of univer- is often continued even in the face of severe infections,
sal availability of sensitive diagnostic tests in underdeveloped further lowering the immune status and increasing thecountries often delay the diagnosis and institution of therapy.
chances of superinfections with other opportunistic or-
ganisms.
Although the available general guidelines from experi-Successful kidney transplantation provides the only
ences in the industrialized nations are valuable in evalu-hope of survival for patients with end-stage renal disease
ating post-transplant infections, variations in the type(ESRD) in economically poor countries with inadequate
and severity of infections in different geographic regionsfacilities for long-term dialysis [1]. In the West, serious
are determined by the epidemiological factors. Infectionsinfections were noted in about 70% of patients, with a
that are endemic in the general population in tropicalfatal outcome in nearly 40% [2]. More recent estimates,
regions are expected to occur with increased frequencyhowever, put the incidence at about 40%. Advances in
among renal transplant recipients in these regions. Indiagnosis, prevention, and therapy have reduced the
addition to recent exposure, disease can also result frommortality to less than 5% in developed countries [3–7].
reactivation of long-dormant focus from a past encounter
with the organism, as in the case of Mycobacterium tuber-
1 Present address: Division of Nephrology, Boston Medical Center, culosis, Strongyloides stercoralis, Leishmania, and cer-
Boston, MA 02110 USA tain viruses belonging to the herpes group. A careful
history of possible exposure to these organisms in remoteKey words: tropical infections, maintenance dialysis, renal transplanta-
tion tuberculosis, fungal infections, viral infections. past must form part of evaluation of infections in a renal
transplant recipient. 2000 by the International Society of Nephrology
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There have been very few attempts to (i) define the tropical regions. Similarly, legionella, an important cause
of post-transplant pneumonia in the temperate climate,pattern of infections among dialysis and transplant pa-
tients in the tropical environment and (ii) to develop has not been reported. In part, this discrepancy could
be accentuated by the lack of awareness and unavailabil-specific preventive, diagnostic and therapeutic strategies
tailored to the specific organisms encountered in the ity of specific diagnostic techniques in these regions.
developing countries.
TUBERCULOSIS
BACTERIAL INFECTIONS Because of its endemicity and the protean ways in
which this disease can present, tuberculosis remains aBacterial infections encountered in patients on main-
tenance dialysis are generally due to Staphylococcus frequent infection among patients on maintenance dial-
ysis and in renal transplant recipients in the tropics.aureus or gram-negative organisms. Common sites are
the respiratory tract and the vascular access sites. Lack Among dialysis patients, the incidence has been reported
to vary between 7–9% in Bangladesh, Indonesia, Unitedof proper hygiene and hot and humid climate promote
colonization of vascular access catheters, leading to septi- Arab Emirates and Saudi Arabia and is more than 10%
in India [17].cemia and right sided endocarditis. The subject has been
reviewed in detail elsewhere [17]. Among renal trans- Compared to the incidence of less than 1% in the
United States and Europe and 4% in the Middle Eastplant recipients, bacterial infections originate most com-
monly from the urinary tract or the lungs [8, 18, 19]. The [20], this infection is encountered in 10–13% of all renal
transplant recipients in the tropical regions [21–26]. Wecausative organisms are the same as those prevalent in
the general population. The etiologic agent often re- observed tuberculosis in 11.8% of patients at our center.
The commonest presentation among transplant recipi-mains unidentified because of unavailability of isolation
techniques, and physicians tend to start broad-spectrum ents in tropics is with pleuropulmonary disease (28–50%)
followed by disseminated tuberculosis. About 20–40%antibiotics on empirical grounds. At our own center,
bacterial infections of the lung were observed in 18% of patients present with fever of undetermined etiology
[21]. The diagnosis is often made retrospectively afterpatients in the first year after transplant. All pulmonary
infections encountered in the first month were of bacte- observing a complete response to antitubercular therapy.
Less commonly, patients present with isolated involve-rial origin. Causative organisms could be identified in
50% of the cases and included Pseudomonas aeruginosa, ment of extrapulmonary sites such as skin [27], bone and
joint [28], gastrointestinal tract [20, 21], larynx [29], renalStaphylococcus aureus, and Klebsiella [18]. As in devel-
oped nations, the urinary tract is the most common allograft [21, 30] and pericardium [25]. Cutaneous tuber-
culosis may present with a nonhealing skin ulcer, andsource of bacterial sepsis following renal transplantation.
Serious complications such as emphysematous pyelone- the diagnosis is made by demonstrating acid-fast bacilli
(AFB) on smears from the ulcer bed or on histology.phritis in an occasional patient may necessitate graft
nephrectomy. Patients with laryngeal tuberculosis present with a long
history of hoarseness of voice and/or odynophagia. TheInfections with enteric organisms such as Salmonella
typhi, S. paratyphi, and Shigella are encountered fre- latter symptom is considered pathognomonic of tubercu-
lar involvement of the larynx. Laryngoscopy shows gran-quently among the general population in the tropics.
There is little evidence that the incidence or course of ulation tissue on the vocal cords. Laryngeal carcinoma
is a close differential diagnosis, and histology usuallythese infections is altered in transplant recipients. Gueco
et al [10] documented Salmonella infection in 5 of their clinches the diagnosis. Diagnosis of tubercular osteomy-
elitis requires a high index of suspicion. Mycobacterial440 patients. Interestingly, two of them were subjected
to nephrectomy in the belief that the graft was acting as involvement of bone has to be present for over 6 weeks
before radiological changes become evident [31]. In-a reservoir for the infection. Non-typhoid Salmonella
species, such as Campylobacter jejuni and Listeria mono- volvement of renal allograft is usually seen as part of
disseminated disease, and should be suspected in patientscytogenes, are being observed with increasing frequency
among renal transplant recipients in western countries who show focal lesions in the allograft on ultrasonogra-
phy and/or CT scan. The diagnosis can be confirmed by[3]. Since these infections originate in the gastrointestinal
tract, these are expected to occur with a higher frequency demonstrating AFB on fine needle aspiration from the
lesion.in tropical countries where gastrointestinal infections are
more common among the general population. No data Although M. tuberculosis is the most common spe-
cies isolated from these patients, infection with atypicalare available, however, on the prevalence or severity of
these infections from the tropical region. Mycobacteria such as M. kansasii, M. marinum, M.
avium-intracellulare and M. fortuitum has also been doc-Nocardial infections have been documented with a
lower frequency among renal transplant recipients in the umented [20]. Since these organisms are much less sensi-
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tive than M. tuberculosis to the conventional antitubercu- development of hepatitis. Another important concern
is the development of drug-resistant tuberculosis. Thelar agents, the species identification by culturing the
specimen on appropriate media assumes considerable incidence of primary INH resistance is increasing stead-
ily [34]. Prophylaxis with INH is therefore not only likelyimportance.
Tuberculosis presents numerous diagnostic difficulties to be ineffective, but has the potential of increasing emer-
gence of resistant bacilli. The American Thoracic Societyin renal transplant recipients. Because of the high fre-
quency of cutaneous anergy in immunosuppressed pa- recommends prophylactic INH administration to Man-
toux-positive patients [35]. This strategy, however, is un-tients, the Mantoux test is generally unhelpful as a diag-
nostic tool. The classic picture of apical involvement on likely to be applicable in endemic areas, both because
of a high degree of Mantoux positivity in the generalchest X ray is seen in only a minority of renal transplant
recipients with pulmonary tuberculosis [18]. Demonstra- population [36] as well as the high frequency of false-
negative tests among chronic renal failure (CRF) pa-tion of AFB in the sputum smear requires repeated ex-
amination on several occasions and has a low yield. Iden- tients. Routine INH prophylaxis is therefore not recom-
mended in endemic areas.tification on culture takes 4–6 weeks. For these reasons,
the diagnosis is often delayed, during which time the
disease continues to spread. Recently, bronchoalveolar
FUNGAL INFECTIONS
lavage (BAL) has been shown to be useful in making
Fungal infections encountered among renal transplantan early and accurate diagnosis of tuberculosis in renal
recipients are either localized mucocutaneous or sys-transplant recipients. AFB could be identified by BAL
temic infections. Mucocutaneous fungal infections arein 88% patients with pulmonary tuberculosis [18]. Bron-
documented in 60–72% of all renal allograft recipientschoscopy and BAL should, therefore, be performed
in the tropical countries [37, 38]. The common organismsearly in patients with unexplained pulmonary infiltrates
responsible for these infections include Tinea corporis,in endemic areas.
T. cutis and T. versicolor (55–65%), followed by CandidaTreatment of post-transplant tuberculosis presents
(7–9%) and Cryptococcus (0–1%). The hot and humidproblems both in the choice of antitubercular agents and
climate, poor hygiene, and frequent use of broad-spec-duration of therapy. Rifampicin is a well known hepatic
trum antibiotics increase the risk of colonization andP-450 microsomal enzyme inducer, increasing the clear-
local spread of these fungi. Oro-esophageal candidiasisance of both prednisolone and cyclosporine A. There
is noted in about 10% of all renal transplant recipientsare no data on glucocorticoid pharmacokinetics in pa-
[39]. The incidence is higher in those on triple immuno-tients on steroids, and it is a common practice to double
suppressive therapy compared to those taking only aza-the prednisolone dose. The dose of prednisolone needs
thioprine and prednisolone. In over 50% of patients,to be doubled and that of cyclosporine increased to al-
the involvement is limited to the esophagus. The usualmost 3–4 fold to maintain therapeutic blood levels. The
presenting feature is dysphagia and, less commonly, gas-latter increases the cost of therapy and is unacceptable
trointestinal bleeding.to a vast majority of patients. An alternative regime that
Topical therapy is usually effective in controlling mu-has been successfully used for these patients consists of
cocutaneous fungal infections [37]. The drugs used in-a combination of isoniazid (INH), pyrazinamide, ci-
clude azoles or terbinafine for cutaneous infections andprofloxacin and ethambutol [21]. The optimum duration
nystatin or clotrimazole for oro-esophageal candidiasis.of therapy is also a matter of debate. Riska et al [32]
Prolonged oral therapy with griseofulvin or fluconazolerecommend treatment of these patients for 9 months.
is necessary in patients with extensive cutaneous diseaseThis therapy may be appropriate for patients with pul-
or involvement of nails. The leukocyte count should bemonary tuberculosis who are on both INH and rifampi-
monitored regularly during griseofulvin therapy to pre-cin, but most centers extend the treatment to 12 months.
vent life-threatening granulocytopenia. A short courseThe duration needs to be increased to 18 months in
of oral fluconazole is effective for esophageal candidiasispatients who are on cyclosporine and are not receiving
that does not resolve with local therapy [39].rifampicin.
Systemic fungal infections are divided into two classes:The role of INH prophylaxis after transplant is contro-
those due to opportunistic organisms such as Candida,versial. In one study carried out in a low-endemicity
Aspergillus, Cryptococcus or Mucor and geographicallyarea, tuberculosis was seen in 22% of high-risk patients,
restricted mycoses, caused by histoplasma, coccidioides,but all patients who had received INH prophylaxis were
blastomycetes. Clinical and autopsy studies put the inci-protected [20]. In contrast, in a study of 184 Indian pa-
dence of fungal infections among renal transplant recipi-tients, John et al [33] did not find any reduction in the
ents in the tropical countries at 4–7% [12, 44, 45]. Thisincidence of this disease in those who received INH
figure is likely to be an underestimate as the infectionsprophylaxis. On the other hand, INH had to be discon-
tinued in a significant proportion of patients because of remain undiagnosed in patients who do not come for
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follow up or are reported to have died and autopsy was fulminant rhinocerebral disease or necrotizing pneumo-
nia with massive hemoptysis [42]. A few cases of zygo-not done. Nampoory et al [41] noted a high incidence
of rejection, graft dysfunction and viral infections in pa- mycosis involving the renal allograft have been encoun-
tered soon after transplantation performed in tropicaltients with fungal infection.
countries [15, 43]. The infection is thought to result from
Candida either direct transmission from the donor or inoculation
at the time of surgery due to poor hygienic conditions inCandidiasis is the most common systemic fungal infec-
tion encountered among renal transplant recipients. Uri- the operation theater or the surgical wards. The primary
treatment in these cases is prompt surgical resection ofnary tract is the site of origin in over 80% of cases [12].
The risk is increased by prolonged indwelling catheter- the involved areas along with systemic amphotericin-B.
Despite all these measures, the mortality exceeds 90%.ization, urinary obstruction, and broad-spectrum antibi-
otics, and it is also higher in diabetics. Secondary obstruc-
Cryptococcosistion may develop due to formation of a fungal ball or
renal papillary necrosis. Regular surveillance cultures Cryptococcosis is a common fungal infection among
renal transplant recipients in tropical areas [12, 48]. Theand prompt treatment of candiduria are necessary to
avoid these complications in asymptomatic high-risk pa- presenting symptoms are related to central nervous sys-
tem involvement (meningoencephalitis), and include atients. Candida infection can also involve the lungs, usu-
ally as a secondary invader in those with a pre-existing nonspecific febrile illness along with chronic headache.
Although respiratory tract is the portal of entry of theinfective or noninfective pulmonary lesion [18]. The di-
agnosis is made by demonstrating the organism on bron- organism, symptoms related to pulmonary involvement
are usually absent [12]. Lack of exudative inflammation ischoalveolar lavage using a sheathed catheter. Sputum
culture is not diagnostic because of the possibility of a characteristic feature of central nervous system (CNS)
cryptococcosis, and signs of meningeal irritation are ab-contamination with pharyngeal secretions where this or-
ganism resides normally. The drug therapy includes oral sent in most cases. Therefore, examination of the cere-
brospinal fluid, including India ink staining and crypto-fluconazole or parenteral low-dose amphotericin-B.
coccal capsular polysaccharide antigen testing, should be
Aspergillus included in the work-up of all transplant recipients with
fever of unexplained origin, especially if headache isPulmonary aspergillosis is reported in a significant pro-
portion of renal transplant recipients in tropical countries a prominent symptom. In some cases, cryptococci can
disseminate and involve other organs including skin[12, 18]. In addition to the risk factors already mentioned,
ongoing construction activities in and around the hospi- [12, 41] and eye [45]. Cutaneous nodules are the initial
presentation in 30% of cases and can be diagnosed easilytals and/or residential areas are responsible for increased
risk of this dreaded infection [3]. Patients present with by biopsy. Oral fluconazole is effective in all except the
most acutely ill patients, who should receive ampho-necrotizing bronchopneumonia or, less commonly, with
involvement of nasal sinuses. Diagnosis requires demon- tericin-B. The optimal duration of therapy is unclear,
and the prognosis is excellent if treatment is started instration of organisms by culture of respiratory secretions
or on histology. Diagnostic sensitivity can be increased time [12].
by bronchoscopy along with bronchoalveolar lavage and/
Pneumocystis cariniior transbronchial biopsy. Treatment is with systemic
amphotericin-B. Large areas of infarction are produced Before the introduction of cotrimoxazole prophylaxis
[2, 4, 46], about 5–10% renal transplant recipients werebecause of the angioinvasive nature of this fungus, sig-
nificantly reducing the penetration of the drug. If the observed to develop pneumonia due to P. carinii. The
frequency is higher in those on cyclosporine [46, 47] andlesion is localized, surgical resection of the infarcted ar-
eas can help by reducing the load of organism. Mortality the period of greatest risk is between 1 and 6 months
after transplantation. Occasional clustering of cases hasis around 50%, increasing to over 90% in disseminated
disease. been reported in the tropical regions [48]. Interstitial
pneumonia leading to respiratory failure is a cardinal
Mucormycosis (zygomycosis) feature, and the mortality approaches 60–100% in those
with this complication. Until recently, this infection wasThis infection is produced by ubiquitous saprophytic
fungi belonging to the order Mucorales and genera Rhi- not well recognized in many tropical countries [49], and
prophylaxis against this organism was not administeredzopus, Absidia, and Mucor. Airborne spores lead to pri-
mary inoculation in humans. Encountered in about routinely at many transplant centers. In a recent prospec-
tive study, 10% of patients not on cotrimoxazole prophy-0.5–1% of all transplant recipients, the risk of this infec-
tion is increased by the presence of diabetes and meta- laxis developed P. carinii pneumonia in the first 6 months
following transplant, and the mortality was 20% [18].bolic acidosis [12]. Presentation can take the form of
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The diagnosis was made with 100% sensitivity with BAL. transmitted by the donor. Lack of data on the pretrans-
plant serologic status of donors and recipients makesCotrimoxazole, in a dose of one single-strength tablet
daily, was effective in completely preventing this infec- any judgment on the nature of CMV disease in tropical
countries as merely speculative. There is a direct correla-tion. Once infection has already set in, treatment re-
quires cotrimoxazole in potentially nephrotoxic doses. tion between the prevalence of anti-CMV antibody and
the socioeconomic conditions of the population [54]. HotAll patients therefore must receive prophylactic therapy
for at least 6 months after transplant. Longer administra- and humid climate, overcrowding, poor hygiene and
large families provide ideal conditions for its spread intion may be necessary in those who have received multi-
ple courses of anti-rejection therapy or have graft dys- the developing countries of the tropical region. Among
Indian adults, the antibody prevalence is 85–100% [55],function.
hence most of the infections are likely to be either reacti-
Other fungi vation or superinfections.
An important effect of CMV infection is an increaseInfections due to other fungi have been reported un-
commonly among renal transplant recipients in tropical in immunosuppression leading to infection with other
opportunistic pathogens. Superinfection has been docu-countries. Of the geographically restricted mycoses, dis-
seminated histoplasmosis has been documented rarely mented in over 90% of all patients with CMV infection
in the tropical region, with tuberculosis and fungi being[50]. The staining characteristics of this organism are
similar to Leishmania donovani, the causative agent of the most common pathogens [53].
The prophylactic and preemptive treatment strategiesKala-azar, and silver stains are required for definitive
identification. Saprophytic fungi of the class Phaeohy- for CMV advocated in the western countries [3] substan-
tially increase the cost of treatment and are not currentlyphomycoses, which are usually nonpathogenic in hu-
mans, cause another type of fungal infection reported feasible in most developing countries. Ganciclovir is ex-
tremely expensive and is not even available in manyfrom the tropics [51, 52]. The common form of presenta-
tion is with localized subcutaneous masses. On histology, underdeveloped countries. The most cost-effective strat-
egy seems to be to restrict ganciclovir treatment for thosethe organisms appear as pigmented, elongated, septate
fungi with swollen tips. Rarely, dissemination can take viremic patients who show clinical evidence of CMV
disease [57]. Recurrence is seen in a minority of casesplace and lead to endocarditis or brain abscess. Surgical
resection is the appropriate primary treatment for local- and requires long-term suppressive therapy.
ized disease. Adjunctive therapy with antifungal drugs
Hepatitismay be needed for relapsing or disseminated disease.
The prevalence of hepatitis B virus (HBV) and hepati-
VIRAL INFECTIONS tis C virus (HCV) infections among dialysis population
in tropical countries varies from 20 to 45% and 7–60%,Cytomegalovirus (CMV) is the most frequent patho-
gen encountered in renal transplant recipients in coun- respectively [17, 56–61]. These figures are significantly
higher compared to their prevalence in the general popu-tries with a temperate climate [2, 3, 8]. About two thirds
of transplant recipients show evidence of infection, but lation. A very high prevalence of hepatitis B antigenemia
up to 82% has been reported in dialysis patients in Tai-clinical disease develops in a much smaller number [3].
Until recently, CMV infection was not well recognized wan, where hepatitis B infection is highly endemic [62].
The prevalence of HCV in the dialysis population wasamong renal transplant recipients in tropical countries
because of lack of proper diagnostic facilities [16, 53]. 35.8% in the same study.
Hepatitis B and C are the major causes of liver diseaseIn a recent study, CMV was documented in 12 of 69
(17%) renal transplant autopsies carried out between in renal transplant recipients [2, 3]. In most instances,
the infection is acquired before transplantation. The1992–1997, compared to one of 27 (4%) during 1980–
1991 [53]. Detection of CMV antigen in peripheral blood modes of transmission include horizontal transmission
from contaminated machines or disposables in dialysispolymorphonuclear leukocytes using monoclonal anti-
bodies to human CMV pp-65 is now being used for con- units, transfusion of contaminated blood products and
transplantation of an infected organ. Immunosuppres-firmation of the diagnosis in some of the advanced cen-
ters in the tropical countries [53]. sive therapy leads to unchecked viral replication, which
in turn leads to chronic liver disease and hepatocellularThe pattern and severity of CMV disease depend upon
the serological status of the recipient and the donor. The carcinoma after many years.
Availability of effective vaccination schedules and ob-disease severity is likely to be greater in a previously
seronegative recipient who receives an infected allograft servation of strict isolation practices have led to a signifi-
cant reduction in the risk of hepatitis B infection in the(primary infection), compared to a seropositive recipient
who develops a reactivation of the latent virus, or in the west. In contrast, as the duration between the diagnosis
of ESRD and transplantation is less than a few months,event of a superinfection with a different strain of virus
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most patients do not complete the immunization sched- after returning to their primary physicians. Most patients
cannot afford expensive antiretroviral therapy, and theule in developing countries [17]. Moreover, facilities for
monitoring antibody titers are not available, hence it only course is withdrawal of immunosuppression and
treatment of intercurrent infections.is difficult to determine if the patient has developed
protective titers. Most dialysis units do not have dedi-
Other viral infectionscated dialysis machines for HBV positive patients,
thereby increasing the risk of horizontal transmission. A number of other viruses belonging to herpes group,
such as Epstein-Barr virus, varicella-zoster virus (VZV),There is little agreement on the criteria for selecting
HBV- or HCV-positive patients for transplant. The deci- herpes simplex virus and human herpesvirus-6 cause dis-
ease with increased frequency and severity among renalsion is based on natural history of the infection and the
availability of alternative forms of treatment, such as transplant recipients. However, data on the incidence or
pattern of disease due to these viruses among transplantdialysis. Data on natural history of hepatitis infections
among transplant recipients in tropical countries are con- recipients in the tropical regions are sparse. In one pro-
spective study of 157 patients [12], herpes zoster wasflicting. In one autopsy study [11], hepatitis was present
in 52% of hepatitis B surface antigen (HBsAg)-positive seen in 11% of cases. Disseminated primary VZV infec-
tion has not been reported among transplant recipientstransplant recipients. In another study of 135 HBsAg-
positive patients, 60% developed acute hepatitis and in the tropics, probably because most individuals have
been exposed to the infection in the childhood. Herpes16% died due to liver failure [58]. Agarwal et al [64]
studied 17 HBsAg-positive patients, 14 of whom also simplex has been documented in 3% patients. The re-
ported incidence of herpes simplex in the west is closeshowed hepatitis B e-antigen (HBeAg) positivity. One
died of fulminant hepatic failure and 4 died due to non- to 50%, with a significant proportion developing lesions
at sites distant from the usual oro-facial or ano-genitalhepatic causes. Of the 12 patients followed up for a mean
duration of 70 months, chronic hepatitis developed in locations.
only 2 cases. On the basis of their data, the authors
recommend transplant in all HBsAg-positive CRF pa-
OTHER INFECTIONS
tients, including those with HBe antigenemia. There are
Visceral leishmaniasisno data on the natural history of HCV infection among
transplant recipients in developing countries. The preva- Visceral leishmaniasis (Kala-azar) is caused by the
protozoan Leishmania donovani, endemic in many partslence of hepatitis G virus among renal transplant recipi-
ents in Thailand has been reported to be 43% [63]. of the tropics including eastern India, parts of Africa
and southwest Asia. The clinical picture is characterizedLack of availability and high cost of dialysis leave these
patients with little alternative other than transplantation, by fever, weight loss, hepatosplenomegaly, cytopenias
and hypergammaglobulinemia. About 20 cases of Kala-and in practice, all HBV- and HCV-positive patients
who do not show evidence of active hepatitis undergo azar have been described in renal transplant recipients,
all but one had either been living in or had traveled totransplantation, irrespective of the other serological
markers. endemic areas [67–69]. The time of onset of infection
varied from 3 months to 8 years following transplanta-The treatment of viral hepatitis after transplant is
highly unsatisfactory. Besides the cost, interferon in- tion. In contrast to the nonorgan recipients, over 50%
of these patients present with superinfections with bacte-creases the risk of graft loss. Recently, lamivudine has
been shown to suppress viral replication and improve rial, viral or fungal organisms. The diagnosis can be es-
tablished by demonstrating the organism on bone marrowliver function tests in a small number of renal transplant
recipients with HBV related chronic active hepatitis [65]. examination. Treatment is with sodium stibogluconate
20 mg/day for 20–30 days. Alternatives include ampho-If shown to be effective in larger samples, this drug may
find a place in the management of post transplant hepati- tericin B (0.5–1 mg/kg/day for a total of 10–20 mg/kg),
pentamidine or a combination of allopurinol, aminosid-tis B and C.
ine, or interferon-g with antimony. More recently, liposo-
Human immunodeficiency virus (HIV) mal amphotericin B (AmBisome; NeXstar Pharmaceuti-
cals Ltd., Cambridge, England, UK) has been usedHIV infection has rarely been reported among renal
transplant recipients in developing countries. In most successfully. The mortality is around 30%, and relapse
is seen in about 30% of the survivors.instances, the virus has been transmitted via a contami-
nated allograft or unscreened blood products. Such situa-
Malariations are more frequently encountered among patients
undergoing commercially-motivated renal transplants Caused by a protozoan belonging to the genus Plasmo-
dium, malaria is of great epidemiological importance in[14, 66]. The diagnosis is made when they present with
one of the AIDS-defining illnesses or upon screening the tropics. It is transmitted by the bite of the Anopheles
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